How did we turn 142 injection pens into a plastic chair? Here’s one of our plastic experts, Niels, explaining just that – and how we work to avoid waste from our pens ending up in the wrong places. 💡 Hint: It’s about collaborating with partners to collect used pens for recycling ♻️ #NovoNordisk #DrivingChange #Recycling
Novo Nordisk
Produktion af lægemidler
Driving change to defeat serious chronic diseases, built upon our heritage in diabetes.
Om os
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
- Websted
-
https://www.novonordisk.com
Eksternt link til Novo Nordisk
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Bagsværd
- Type
- Aktieselskab
- Grundlagt
- 1923
- Specialer
- Pharmaceuticals, Insulin, obesity, Rare Diseases og Diabetes
Beliggenheder
Medarbejdere hos Novo Nordisk
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Naras Eechambadi
Global Leader in Data & AI | C-Suite Executive | Board Director | DataIQ Top10 | Executive Coach
-
Sören Meelby
Strategic Alliance Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Opdateringer
-
160 million children are affected by obesity. Our new Childhood Obesity Prevention Initiative (COPI), built on a decade learning of Cities for Better Health, is launching in six cities across the world. We’re aiming to establish impactful and scalable solutions that work for people in some of the most disadvantaged communities. Read more here: https://lnkd.in/dyuvY9-v #DrivingChange #ChildhoodObesity #HealthEquity
-
We are so proud of Lotte Bjerre Knudsen! She was just honoured with The Lasker~DeBakey Clinical Medical Research Award by The Albert and Mary Lasker Foundation for her groundbreaking work in advancing GLP-1-based medicines for the treatment of obesity. Lotte is a true leader and pioneer, developing the first ever long-acting GLP-1 and continuously advocating for a dual focus on obesity and diabetes. This award highlights her perseverance and dedication to GLP-1 research and development for more than 30 years - contributions that make a significant impact on the people we serve every day. Join us in congratulating Lotte for this prestigious recognition. We are honoured to have her as a member of our Novo Nordisk family 💙 #DrivingChange #WomenInScience #LaskerAwards
-
Are you a master's student looking to kick-start a global career with one of the world's leading pharmaceutical companies? Then the Novo Nordisk global Graduate Programme could be the next step for you! Throughout October and November, we're hosting a series of live webinars to provide insights into our two-year Graduate Programme, which allows you to explore the world, while developing your career 🌏💼 Join one of the 10 webinars to hear directly from our graduates and programme managers and gain an in-depth look into the specific tracks, the everyday life as a graduate, career development opportunities, and learn about the exciting journey ahead! 💻 Sign up for the upcoming webinars here 👉 https://brnw.ch/21wNiHO
-
Cardiovascular disease is a significant health challenge. We all likely know someone affected by it, making it personal for us. In recognition of #WorldHeartDay on 29 September, we are renewing our heartfelt commitment to reduce the risk and burden of people living with this disease. Join us in our heartfelt commitment by leaving a ❤️ in the comment section. Your participation makes a difference. Together, we are #DrivingChange in #CardiovascularDisease To learn more visit 👉 https://lnkd.in/d_8_t33U #ItsHeartfelt #UseHeart
-
🤝 Partnerships 💧 Circularity ♻️ Recycling These are just some of the ways we are working to speed up our transition towards a more sustainable future. Curious to learn more about our sustainability initiatives? Get the key highlights from some of our own experts. #DrivingChange #Sustainability
-
Looking to turn your master’s degree into a global career in 2025? 🚀 Each year, Novo Nordisk is on the lookout for new talents to join the global Graduate Programme spanning across various tracks within technology, pharmaceutical development, marketing, supply chain and many others. The two-year programme allows you to explore the world through multiple rotations, while developing your career. Learn more and sign up to our global talent hub to stay up to date about the graduate programme here💻 👉 https://brnw.ch/21wMI8p
-
Congratulations to Team Novo Nordisk's Para-cyclist Kate Brim for winning gold and bronze on the world's biggest stage and representing the entire #diabetes community. Kate's hard work and dedication inspire us, as do her wise words: “bad things do happen; how I respond to them defines my character and the quality of my life.” We are looking forward to following her journey as she continues to show what is possible with diabetes. #TeamNovoNordisk #Type1Diabetes #GoldMedalist Photo credit: SWpix
-
A week buzzing with excitement! We're thrilled to have welcomed a new group of talented graduates, ready to make their mark on different business areas, such as Technology, Pharmaceutical Development, Supply Chain, Finance and many more. The 81 new graduates, representing 25 nationalities, will experience at least three rotations, giving them the opportunity to explore the world while developing their careers. A warm welcome and good luck to all of you! Eager to turn your master’s degree into a global career? Applications for the 2025 global Graduate Programme open this November. Learn more 👉 https://lnkd.in/dJv2Vng8
Tilsvarende sider
Aktie
NVO
NYSE
20 minutters forsinkelse
120,04 US$
2,51 (2,136 %)
- Åbningspris
- 119,92
- Lavpunkt
- 119,48
- Højdepunkt
- 120,56
Data fra Refinitiv
Få flere oplysninger påFinansiering
Seneste runde
Post IPO-egenkapital22.000.000,00 US$